

Subst. Form PTO-1449		O I P E FEB 09 2001 P A T E N T & T R A D E M A R K S E R V I C E S U. S. PATENT AND TRADEMARK OFFICE Applicant 56290-054 S CROL-132CP		Application Number 09/647,726	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>					
				Kevin R. Stone et al.	
		Filing Date 12/4/00		Group Art Unit 3738	

U. S. Patent Documents

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
VA	A-29	5,865,849	2/99	Stone	623	18	
VA	A-30	5,902,338	5/99	Stone	623	13	
	A-31	5,904,716	5/99	Gendler	623	11	
	A-32	5,922,027	7/99	Stone	623	11	
	A-33	5,944,755	8/99	Stone	623	16	
	A-34	5,984,858	11/99	Stone	600	20	
	A-35	6,046,379	4/00	Stone et al.	623	11	
	A-36	6,049,025	4/00	Stone et al.	128	898	
VA	A-37	6,110,206	8/00	Stone	623	13.11	

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
VA	B-1	WO 84/03036	8/84	PCT				
VA	B-2	WO 95/28412	10/95	PCT				
VA	B-3	WO 95/33828	12/95	PCT				
VA	B-4	WO 95/26740	10/95	PCT				
VA	B-5	EP 347,496	12/89	EP				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

VA	C-1	Rodrigo et al., "Osteocartilaginous Allografts as Compared with Autografts in the Treatment of Knee Joint Osteocartilaginous Defects in Dogs", Clinical Orthopedics and Related Research, 134, pp. 342-349 (1978).
VA	C-2	Webber et al., "Cell Culture of Rabbit Meniscal Fibrochondrocytes: Proliferative and Synthetic Response to Growth Factors and Ascorbate", Journal of Orthopedic Research, 3, pp. 36-42 (1985).
VA	C-3	Collins et al., "Characterization of Porcine Endothelial Cell Determinants Recognized by Human Natural Antibodies", Xenotransplantation, 1, pp. 36-46 (1994).
VA	C-4	LaVecchio et al., "Enzymatic Removal of Alpha-Galactosyl Epitopes From Porcine Endothelial Cells Diminishes The Cytotoxic Effect of Natural Antibodies", Transplantation, 60, pp. 841-847 (1995).

EXAMINER	V. Amanova	DATE CONSIDERED	8/27/02
----------	------------	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy with next communication to applicant.

Subst. Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)



Docket Number (Optional)

56290-054
CROL-132CP

Application Number

09/647,726

Applicant

Kevin R. Stone et al.

Filing Date

12/4/00

Group Art Unit

3738

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

VA	C-5	Cotterell et al., "The Humoral Immune Response in Humans Following Cross-Perfusion of Porcine Organs", Transplantation, 60, pp. 861-868 (1995).
↑	C-6	Galili, "Interaction of the Natural Anti-Gal Antibody with α -Galactosyl Epitopes: a Major Obstacle for Xenotransplantation in Humans", Immunology Today, 14, pp. 480-482 (1993).
	C-7	Elves et al., "An Investigation Into The Immunogenicity Of Various Components of Osteoarticular Grafts", The British Journal of Experimental Pathology, 55, pp. 344-351 (1974).
	C-8	Derby et al., "The Histochemical Specificity of Streptomyces Hyaluronidase and Chondroitinase ABC", Histochemical Journal, 10, pp. 529-547 (1978).
	C-9	Homandberg et al., "High Concentrations of Fibronectin Fragments Cause Short-Term Catabolic Effects in Cartilage Tissue While Lower Concentrations Cause Continuous Anabolic Effects", Archives of Biochemistry and Biophysics, 311:2, pp. 213-218 (1994).
	C-10	Homandberg et al., "Agents That Block Fibronectin Fragment-Mediated Cartilage Damage Also Promote Repair", Inflamm. Res., 46, pp. 467-471 (1997).
	C-11	Homandberg et al., "Exposure of Cartilage to a Fibronectin Fragment Amplifies Catabolic Processes While Also Enhancing Anabolic Processes to Limit Damage", Journal of Orthopaedic Research, 16, pp. 237-246 (1998).
	C-12	Homandberg et al., "Association of Proteoglycan Degradation with Catabolic Cytokine and Stromelysin Release from Cartilage Cultured with Fibronectin Fragments", 334:2, pp. 325-331 (1996).
	C-13	Lipman et al., "Xenografts of Articular Chondrocytes in the Nude Mouse", Calcif. Tissue Int., 35, pp. 767-772 (1983).
	C-14	Stone et al., "Porcine and Bovine Cartilage Transplants in Cynomolgus Monkey: I. A Model for Chronic Xenograft Rejection", Transplantation, 63, pp. 640-645 (1997).
	C-15	Galili et al., "Porcine and Bovine Cartilage Transplants in Cynomolgus Monkey: II. Changes in Anti-Gal Response During Chronic Rejection", Transplantation, 63, pp. 646-651 (1997).
	C-16	Stedman's Medical Dictionary, Williams & Wilkins, 26 ed., pp. 221, 793, 1070, 1966 (1995).
VA	C-17	Galili et al., "Man, Apes, and Old World Monkeys Differ from Other Mammals in the Expression of α -Galactosyl Epitopes on Nucleated Cells", J. Biol. Chem., 263, 17755-17762 (1988).

EXAMINER

V. Agunma

DATE CONSIDERED

8/27/02

MAIL ROOM
2001RECEIVED
JULY 2001

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy with next communication to applicant.

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy with next communication to applicant.

Paper #5

Subst. Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				Docket Number (Optional) 56290-054 CROL-132CP	Application Number 09/647,726		
				Applicant Kevin R. Stone et al.			
				Filing Date 12/4/00	Group Art Unit 3738		
U. S. Patent Documents							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
VA	A-1	4,400,833	8/83	Kurland	3	1	
VA	A-2	4,585,585	4/86	Waite	260	112.5R	
VA	A-3	4,597,266	7/86	Entrekin	62	46	
VA	A-4	4,609,627	9/86	Goldstein	435	269	
VA	A-5	4,627,853	12/86	Campbell et al.	623	16	
VA	A-6	4,642,120	2/87	Nevo et al.	623	16	
VA	A-7	4,678,470	7/87	Nashef et al.	623	16	
VA	A-8	4,755,593	7/88	Lauren	530	356	
VA	A-9	4,789,663	12/88	Wallace et al.	514	21	
VA	A-10	4,801,299	01/89	Brendel et al.	623	1/02	
VA	A-11	4,880,429	11/89	Stone	623	18	
VA	A-12	4,932,973	06/90	Gendler	623	16	
VA	A-13	5,067,962	11/91	Campbell et al.	623	13	
VA	A-14	5,071,741	12/91	Brockbank	435	1	
VA	A-15	5,131,850	7/92	Brockbank	435	1	
VA	A-16	5,160,313	11/92	Carpenter et al.	600	36	
VA	A-17	5,171,660	12/92	Carpenter et al.	435	1	
VA	A-18	5,192,312	3/93	Orton	623	2	
VA	A-19	5,206,023	4/93	Hunziker	424	423	
VA	A-20	5,216,126	6/93	Cox et al.	530	350	
VA	A-21	5,306,304	4/94	Gendler	623	16	
VA	A-22	5,333,626	08/94	Morse et al.	128	898	
VA	A-23	5,516,532	5/96	Atala et al.	424	548	
VA	A-24	5,613,982	3/97	Goldstein	623	11	
VA	A-26	5,632,778	5/97	Goldstein	623	11	
VA	A-27	5,681,353	10/97	Li et al.	623	18	
VA	A-28	5,782,915	7/98	Stone	623	11	
EXAMINER V. Afrimova				DATE CONSIDERED 8/27/02			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy with next communication to applicant.